Stem Cell Therapeuti (SCTPF) 0.3372 $SCTPF
Stem Cell Therapeutics Graduates to the Toronto Stock Exchange
Marketwire - Mon Apr 21, 6:01AM CDT
Stem Cell Therapeutics Corp. ("SCT"
(TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announces that its common shares have been approved for listing and will commence trading on the Toronto Stock Exchange ("TSX" at the opening of the TSX on April 22, 2014. The Company's common shares will continue to trade under the trading symbol "SSS" and its common shares will be delisted from the TSX Venture Exchange concurrent to the commencement of trading on the TSX.
Stem Cell Therapeutics Strengthens its Board of Directors
Marketwire - Mon Mar 10, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the Company's Board of Directors.
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Marketwire - Thu Jan 30, 6:38AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, is pleased to announce that its Board of Directors has elected Dr. Calvin R. Stiller as Chairman of the Board. Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.
Stem Cell Therapeutics Announces Resignation of Director
Marketwire - Mon Jan 27, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, announces that effective today, Mr. David Allan has resigned from its board of directors.
Stem Cell Therapeutics Provides Corporate Update
Marketwire - Mon Jan 13, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today provided the following six-month corporate update:
Stem Cell Therapeutics Appoints Dr. Robert Kirkman to Its Board of Directors
Marketwire - Tue Dec 17, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that industry veteran Dr. Robert L. Kirkman has been appointed to the Company's Board of Directors.
Stem Cell Therapeutics Completes $33 Million Private Placement
Marketwire - Fri Dec 13, 3:50PM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell- related therapeutics, is pleased to announce that it has raised gross proceeds of $33 million through a private placement of units. The financing proceeds will be used to advance the Company's CD47 cancer stem cell program through IND-enabling studies, manufacturing and phase 1 clinical trials.
Stem Cell Therapeutics Adopts Shareholder Rights Plan
Marketwire - Tue Sep 17, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announces that it has adopted a shareholder rights plan (the "Plan" effective September 16, 2013. The Company will be seeking shareholder approval of the Plan at its next annual general and special meeting of shareholders.
Stem Cell Therapeutics Advances CD47 Antagonist Program Into IND-Enabling Phase
Marketwire - Mon Sep 09, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell- related therapeutics, today announced that it has advanced its CD47 antagonist program into an Investigational New Drug (IND) enabling phase. In collaboration with a contract manufacturing organization, Stem Cell Therapeutics (SCT) will begin the manufacturing process to generate drug for formal toxicology studies and a subsequent phase I clinical study, which is anticipated to begin in H2/2015.
Stem Cell Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
Marketwire - Fri Sep 06, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City. Dr. Niclas Stiernholm, the CEO of Stem Cell Therapeutics, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Stem Cell Therapeutics Graduates to the Toronto Stock Exchange
Marketwire - Mon Apr 21, 6:01AM CDT
Stem Cell Therapeutics Corp. ("SCT"
(TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announces that its common shares have been approved for listing and will commence trading on the Toronto Stock Exchange ("TSX" at the opening of the TSX on April 22, 2014. The Company's common shares will continue to trade under the trading symbol "SSS" and its common shares will be delisted from the TSX Venture Exchange concurrent to the commencement of trading on the TSX. Stem Cell Therapeutics Strengthens its Board of Directors
Marketwire - Mon Mar 10, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the Company's Board of Directors.
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Marketwire - Thu Jan 30, 6:38AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, is pleased to announce that its Board of Directors has elected Dr. Calvin R. Stiller as Chairman of the Board. Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.
Stem Cell Therapeutics Announces Resignation of Director
Marketwire - Mon Jan 27, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, announces that effective today, Mr. David Allan has resigned from its board of directors.
Stem Cell Therapeutics Provides Corporate Update
Marketwire - Mon Jan 13, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today provided the following six-month corporate update:
Stem Cell Therapeutics Appoints Dr. Robert Kirkman to Its Board of Directors
Marketwire - Tue Dec 17, 6:01AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that industry veteran Dr. Robert L. Kirkman has been appointed to the Company's Board of Directors.
Stem Cell Therapeutics Completes $33 Million Private Placement
Marketwire - Fri Dec 13, 3:50PM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell- related therapeutics, is pleased to announce that it has raised gross proceeds of $33 million through a private placement of units. The financing proceeds will be used to advance the Company's CD47 cancer stem cell program through IND-enabling studies, manufacturing and phase 1 clinical trials.
Stem Cell Therapeutics Adopts Shareholder Rights Plan
Marketwire - Tue Sep 17, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announces that it has adopted a shareholder rights plan (the "Plan"
effective September 16, 2013. The Company will be seeking shareholder approval of the Plan at its next annual general and special meeting of shareholders. Stem Cell Therapeutics Advances CD47 Antagonist Program Into IND-Enabling Phase
Marketwire - Mon Sep 09, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell- related therapeutics, today announced that it has advanced its CD47 antagonist program into an Investigational New Drug (IND) enabling phase. In collaboration with a contract manufacturing organization, Stem Cell Therapeutics (SCT) will begin the manufacturing process to generate drug for formal toxicology studies and a subsequent phase I clinical study, which is anticipated to begin in H2/2015.
Stem Cell Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
Marketwire - Fri Sep 06, 6:01AM CDT
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City. Dr. Niclas Stiernholm, the CEO of Stem Cell Therapeutics, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
